DDX1: A Drug Target / Disease Biomarker (G1653)

Target Name: DDX1

NCBI ID: G1653

DDX1

DDX1: A Drug Target / Disease Biomarker

DDX1 (doublecortin) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is a small protein that is made by the brain and is found in high concentrations in the Planning and Execution (P) and Prefrontal cortex (PFC) of the brain.

Research has shown that DDX1 is involved in the formation of neurofibrillary tangles and neuroplasm in the PFC, which are thought to play a role in the development of neurodegenerative diseases. It is also involved in the regulation of the levels of a protein called BACE1, which is known to be a risk factor for Alzheimer's disease.

In addition to its role in the development of neurodegenerative diseases, DDX1 has also been shown to have potential as a drug target. Studies have shown that inhibiting the activity of DDX1 has the potential to reverse the cognitive decline associated with neurodegenerative diseases.

One way to target DDX1 is through the use of small molecules, such as rapamycin and curcumin. These molecules act by binding to the DDX1 protein and inhibiting its activity. Studies have shown that these small molecules have the potential to reverse the cognitive decline associated with neurodegenerative diseases.

Another way to target DDX1 is through the use of antibodies. Studies have shown that antibodies directed against DDX1 have the potential to reverse the cognitive decline associated with neurodegenerative diseases.

In conclusion, DDX1 is a protein that is expressed in the brain and is involved in the development and progression of neurodegenerative diseases. It is also involved in the regulation of the levels of a protein called BACE1 and has the potential as a drug target. Studies have shown that inhibiting the activity of DDX1 and using small molecules and antibodies have the potential to reverse the cognitive decline associated with neurodegenerative diseases. Further research is needed to fully understand the role of DDX1 as a drug target and its potential as a treatment for neurodegenerative diseases.

Protein Name: DEAD-box Helicase 1

Functions: Acts as an ATP-dependent RNA helicase, able to unwind both RNA-RNA and RNA-DNA duplexes. Possesses 5' single-stranded RNA overhang nuclease activity. Possesses ATPase activity on various RNA, but not DNA polynucleotides. May play a role in RNA clearance at DNA double-strand breaks (DSBs), thereby facilitating the template-guided repair of transcriptionally active regions of the genome. Together with RELA, acts as a coactivator to enhance NF-kappa-B-mediated transcriptional activation. Acts as a positive transcriptional regulator of cyclin CCND2 expression. Binds to the cyclin CCND2 promoter region. Associates with chromatin at the NF-kappa-B promoter region via association with RELA. Binds to poly(A) RNA. May be involved in 3'-end cleavage and polyadenylation of pre-mRNAs. Component of the tRNA-splicing ligase complex required to facilitate the enzymatic turnover of catalytic subunit RTCB: together with archease (ZBTB8OS), acts by facilitating the guanylylation of RTCB, a key intermediate step in tRNA ligation (PubMed:24870230). Component of a multi-helicase-TICAM1 complex that acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA) and plays a role in the activation of a cascade of antiviral responses including the induction of pro-inflammatory cytokines via the adapter molecule TICAM1. Specifically binds (via helicase ATP-binding domain) on both short and long poly(I:C) dsRNA (By similarity)

The "DDX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets